cholesterol induced regulator of metabolism RNAGenealiases: CHROME · PRKRA-AS1
Q-omics provides the consensus-scored CHROMR profile across patient tissues and cancer cell-line models. CHROMR expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, CHROMR is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, CHROMR RNA expression shows 20,663 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight ACC, HNSC, and UVM as cancer lineages where CHROMR shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CHROMR — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CHROMR survival associations across molecular data types. CHROMR RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CHROMR RNA expression–survival associations across cancer types. High CHROMR expression shows unfavorable associations in ACC, STAD, KIRC and LGG, but favorable associations in UCS and BRCA. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for CHROMR RNA expression.
This table summarizes CHROMR tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for CHROMR. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CHROMR shows lower tumor expression in THCA, LUAD, KICH and BRCA and higher tumor expression in HNSC and LIHC. The HNSC box plot shows higher CHROMR RNA expression in tumor versus normal tissue (log2 FC = +1.224, t-test p < 0.001).
This table shows molecular features associated with CHROMR in patient tissues and cancer cell lines. In patient samples, CHROMR shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
